Chemistry:Brezivaptan
From HandWiki
Brezivaptan[1] (developmental code names ANC-501, THY-1773, TS-121) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[2][3][4] As of November 2022, it is in phase II clinical trials for this indication.[2][3][5]
See also
- ABT-436
- Balovaptan
- List of investigational antidepressants
- Nelivaptan
- SRX-246
References
- ↑ PubChem. "Brezivaptan" (in en). https://pubchem.ncbi.nlm.nih.gov/compound/56952080.
- ↑ 2.0 2.1 "TS 121 -". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800041804.
- ↑ 3.0 3.1 "New Drug Pipeline - Taisho Pharmaceutical Holdings". http://www.taisho-holdings.co.jp/en/ir/finance/development/.
- ↑ "Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study". Journal of Psychiatric Research 128: 43–51. September 2020. doi:10.1016/j.jpsychires.2020.05.017. PMID 32521250.
- ↑ "Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data". Biopharmaceutics & Drug Disposition 42 (5): 204–217. May 2021. doi:10.1002/bdd.2273. PMID 33734452.
External links
- Clinical trial number NCT03093025 for "A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder" at ClinicalTrials.gov
 |  |
